QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry 期刊论文 2018, 卷号: 132 作者:  Taher, Ali;  Yassin, Mohamed A.;  Xiao, Zhijian;  Hou, Hsin-An;  Tuglular, Tulin 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 Impact of Myeloproliferative Neoplasms (MPNs) on Health-Related Quality of Life (HRQOL) and Medical Resource Utilization: Results from the MERGE Registry 会议论文 BLOOD, 2018-11-29 作者:  Taher, Ali;  Yassin, Mohamed A.;  Xiao, Zhijian;  Hou, Hsin-An;  Tuglular, Tulin 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03 Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis 期刊论文 Leukemia and lymphoma, 2015, 卷号: 56, 期号: 7, 页码: 2067-2074 作者:  Jung, Chul Won;  Shih, Lee-Yung;  Xiao, Zhijian;  Jie, Jin;  Hou, Hsin-An 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/17 Myelofibrosis  JAK1/JAK2 inhibitor  phase 2  Asian patient population   Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis 期刊论文 2015, 卷号: 56, 期号: 7, 页码: 2067-2074 作者:  Jung, Chul Won;  Shih, Lee-Yung;  Xiao, Zhijian;  Jie, Jin;  Hou, Hsin-An 收藏  |  浏览/下载：16/0  |  提交时间：2020/01/13 Myelofibrosis  JAK1/JAK2 inhibitor  phase 2  Asian patient population